Abstract
Biologics are becoming increasingly important for the potential treatment of widespread diseases such as cancer, anemia, and diabetes. As hundreds of biologics are going off-patent, the market has become ripe for the introduction of generic biologics. A regulatory pathway for biogenerics, however, is virtually nonexistent. The purpose of this paper is thus to analyze how a successful legislative pathway for generic biologics might be designed. The current regulatory scheme, economic concerns, health and safety concerns, and the need to provide proper incentives for innovation are analyzed. Finally, recent Congressional bills are outlined and critiqued, through which the structure of a successful pathway for biogeneric approval can be understood.
Recommended Citation
Kathleen R. Kelleher,
FDA Approval of Generic Biologics: Finding a Regulatory Pathway,
14
Mich. Telecomm. & Tech. L. Rev.
245
(2007).
Available at:
https://repository.law.umich.edu/mttlr/vol14/iss1/8